CORONAVIRUS

AstraZeneca's same vaccine is manufactured and marketed in India as Covishield.

Updated : May 2, 2024

'Covaxin was developed with safety focus’: Bharat Biotech on Covishield blood clot row

AstraZeneca has said that in “very rare cases”, its Covid-19 vaccine can cause low platelet count and a blood clot-related side effect – Thrombosis Thrombocytopenia Syndrome (TTS)

Saurabh Bharadwaj said that many people speculate a connection between the coronavirus vaccine and deaths of young people due to collapsing.

Updated : May 1, 2024

'India continued with Covishield even after adverse reports': AAP's Saurabh Bharadwaj targets Centre as AstraZeneca admits side effect

The AAP leader's remarks came a day after British pharma giant AstraZeneca admitted in a UK court that its anti-COVID vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases."

In India, the Vaxzevria vaccine of AstraZeneca was produced by Adar Poonawalla-led Serum Institute of India (SII) and marketed as Covishield.

Updated : May 1, 2024

'Sympathy goes out to anyone who lost loved ones,' says AstraZeneca on Covishield row

The admission came a day after the pharma giant admitted in a UK court that its COVID-19 vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases".

In India, Covishield is manufactured by the Serum Institute of India (SII) under a licensing agreement with AstraZeneca.

Updated : Apr 30, 2024

AstraZeneca's admission of Covishield risk may spark legal battles in India

The vaccine producer stated in court documents that the inoculation could occasionally induce Thrombosis with Thrombocytopenia Syndrome (TTS), a disorder resulting in blood clots and a reduced platelet count, as reported in The Telegraph.

CORONAVIRUS

'Covaxin was developed with safety focus’: Bharat Biotech on Covishield blood clot row

'India continued with Covishield even after adverse reports': AAP's Saurabh Bharadwaj targets Centre as AstraZeneca admits side effect

'Sympathy goes out to anyone who lost loved ones,' says AstraZeneca on Covishield row

AstraZeneca's admission of Covishield risk may spark legal battles in India

HOT STOCKS

TOP VIDEOS